Floatz logo

HYDROMORPHON

Multiple Myeloma

SanofiSmall moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
59/ 100

Competitive context

343 Active assets in the Multiple Myeloma cohort.

Asset / SponsorPhaseRating
Thalidomide
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
Inno-206
GlaxoSmithKline
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
Janssen Research & Development, LLC
Phase 4BB
PREDNISONE TABLETS
GlaxoSmithKline
Phase 4BB
Carfilzomib
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

HYDROMORPHON is also rated in:

substance-related disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Low Back PainDormant
BBB
Indicative ·
72 / 100
View asset →
Analgesics, OpioidDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →